Preparaci n de abstracts y posters para congresos

1. Preparaci�n de abstracts y posters para congresos Alfredo Prieto Mart�n Profesor Asociado de Inmunolog�a Coordinador del programa de doctorado en Inmunolog�a, Menci�n de calidad MECD Universidad de Alcal� alfredo.prieto@uah.es http://www.alfredoprieto.tk

2. C�mo se hace un abstract para un congreso Se escoge un t�tulo Se enumera a los autores Introducci�n Background Objetivo Material y m�todos Resultados Conclusiones Si el congreso es nacional es seguro que te lo aceptar�n al menos como poster.

3. Uso de PP para hacer un poster a partir de un simple abstract Configurar pagina para poner las dimensiones de ancho y alto ej. 90 x 100 Escoger fondo, poner el zoom en ajustar Cortar y pegar las distintas partes del abstract (Titulo y autores, introducci�n, materiales y m�todos, resultados, y conclusiones) en cuadros de texto. Maquetaci�n de los cuadros de texto se organizan en dos o tres columnas como las de los periodicos.

4. Uso de PP para hacer un poster a partir de un simple abstract Colorear los cuadros de texto usando fondos degradados en dos colores: color de relleno> efectos de relleno >efectos de relleno>dos colores A�adir iconografia (tablas y figuras) que ilustren los resultados Llevar el archivo de PP a un servicio de reprograf�a o ilustraci�n cient�fica que disponga de ploter (30 euros en la UAH)

5. A new paradigm explains dual effects of IL-2 on decisions to cell growth or apoptosis of T cells studied by CSFE tracking and cell enumeration* A Prieto, * D D�az, * H Barcenilla, * G Revilla, * P Prieto, *J Monserrat ,* V Sualdea, *,� M �lvarez Mon-Soto* Department of Medicine, CSIC R&D Associated Unit University of Alcal�, Alcal� de Henares, Madrid, Spain. � Immune System Diseases and Oncology Service, University Hospital �Pr�ncipe de Asturias�, Alcal� de Henares, Madrid, Spain. Background: The responses of lymphocytes to mitogens are heterogeneous, they can remain either in resting state or blastify and in each of these states can also initiate apoptosis. Material and methods: We enumerated CSFE labeled T cells from phenotypically defined subsets, monitorized the process of cell decision between growth and apoptosis and studied how exogenous IL-2 (eIL-2) affects such cell decisions subsequent to mitogen stimulation. The viable and apoptotic cells within resting and blastic cell populations were enumerated 3 days after the policlonal stimulation. For the analysis the undivided cells were classified into 4 categories: viable resting, apoptotic resting, viable blasts and apoptotic blasts. The cells which have suffered cell divisions were classified into viable and apoptotic blasts. Results. At 3 days of culture a high proportion of resting T cells have suffered apoptosis. Some of the blasts suffered apoptosis before their first division. The absolute cell numbers of all subtypes of viable T cells (resting cells, undivided blasts and divided blasts) at 3 days were significantly lower in cultures with eIL-2. At 5 and 7 days of culture eIL-2 increased the number and the viability of the progeny of blasts decreasing their proportion of apoptotic cells within each division. The CSFE tracking demonstrates that eIL-2 allows T cells exceed their third division and continue dividing until five or more divisions. Conclusions: eIL-2 has opposed effects on mature T lymphocytes activated by mitogens before their first division and after it. Firstly it induces apoptosis on them and inhibit their transformation in blasts while later in the blasts inhibits their apoptosis decreasing the proportion of apoptotic cells and induces their growth increasing the number of divisions of the proliferating T cells. So IL-2 is a potent proapoptotic factor for mitogen stimulated mature T lymphocytes and a vigorous growth factor for surviving proliferating blasts.